This is the first article in a series on blood tests and biomarkers for longevity. The series covers five areas in depth: metabolic health, cardiovascular risk, hormonal balance, organ function, and nutritional status. This article explains why the standard annual panel misses most of what matters, and maps the terrain the series will cover.

The half who looked fine

In 2009, a team of researchers analyzed lipid panels from 136,905 hospitalizations for coronary artery disease across hospitals participating in the Get With The Guidelines program. They were not looking for outliers. They were trying to understand the baseline lipid profile of patients arriving with established heart disease.

What they found was striking: nearly half (49.6 percent) had LDL cholesterol levels below 100 mg/dL. Under most clinical guidelines, that is the target for high-risk patients. Under many standard lab reference ranges, it would not even be flagged. These were patients with documented coronary artery disease, many of them arriving for a heart attack, with LDL readings that their lab report would have printed in black ink rather than red.^[1]

This is not a rare anomaly or a flaw in one dataset. It is the expected outcome of a fundamental problem with how we use blood tests. Normal, as printed on your lab report, does not mean healthy. It does not mean low risk. It means something far more specific, and far less useful, than most people realize.

What “normal” actually means

When a lab prints a reference range next to your result, the range was not derived from studies of healthy people. It was not calibrated to outcomes like cardiovascular disease, cancer, or longevity. It was calculated statistically from a large group of tested individuals: take the distribution of results across the testing population, identify the 2.5th and 97.5th percentiles, and define everything in between as normal.

This is called a reference interval, and it has one job: to describe the middle 95% of people who got tested. Not the healthiest 95%. Not the people who went on to live the longest. The middle 95% of whoever happened to show up at a clinic and have that marker measured.

In practice, that population skews older, sicker, and more metabolically compromised than the general population. People who feel entirely well rarely get comprehensive blood work done. The people who do tend to have reasons: symptoms, risk factors, chronic conditions, or a doctor who noticed something. The reference range for fasting glucose, for instance, is calibrated partly against a population that includes a meaningful proportion of people with undiagnosed pre-diabetes. Being in the normal range for fasting glucose tells you that you are not an outlier in that population. It does not tell you that your glucose regulation is optimal.

The distinction matters because the gap between “not flagged” and “optimal” can be wide, silent, and years long. Insulin resistance typically develops over a decade before fasting glucose crosses into the abnormal range. Arterial plaque can accumulate for years with LDL sitting in the normal band. Thyroid dysfunction can suppress energy, cognition, and metabolic rate while TSH stays technically within reference. None of these trajectories trigger an alert on a standard lab report.

Three places where normal masks real risk

The problem is not theoretical. Here are three markers where the gap between the lab’s reference range and what actually matters for health is well-documented and consequential.

ApoB versus LDL cholesterol

Standard lipid panels measure LDL cholesterol, which reflects the mass of cholesterol carried in LDL particles. What drives atherosclerosis (the buildup of plaque in arterial walls) is not the cholesterol mass but the number of LDL particles, because each particle can penetrate the arterial wall independently of how much cholesterol it carries. ApoB is a protein that sits on the surface of every atherogenic lipoprotein particle: one ApoB per particle, without exception. ApoB is therefore a direct count of atherogenic particle number.

LDL and ApoB are correlated on average across populations, but they diverge substantially in individuals, particularly in people with metabolic syndrome, elevated triglycerides, or small dense LDL patterns. A meta-analysis of 233,455 participants found that ApoB predicted cardiovascular events more precisely than LDL cholesterol or non-HDL cholesterol across all studied populations.^[2] A person with normal LDL can have elevated ApoB. Standard lipid panels do not order ApoB. Most lab reports do not mention it. Most general practitioners do not discuss it.

HOMA-IR and fasting insulin

The most common marker of glucose metabolism on a standard panel is fasting glucose. A result below 100 mg/dL is typically printed as normal. The problem is that fasting glucose is the last thing to become abnormal in the trajectory toward type 2 diabetes.

Insulin resistance, the condition where cells respond poorly to insulin, requiring the pancreas to produce progressively more insulin to maintain glucose control, can be established for five to ten years before fasting glucose crosses the threshold the lab considers abnormal. During that entire period, glucose stays normal because the pancreas is compensating. The signal being suppressed is the insulin itself, which is rising to maintain glucose levels that look fine on a report. Fasting insulin is not ordered on most standard panels. Without it, HOMA-IR (the homeostasis model assessment of insulin resistance, calculated as fasting glucose multiplied by fasting insulin divided by 405) cannot be derived, and the decade of early warning remains invisible.^[3]

hsCRP

High-sensitivity C-reactive protein is a marker of systemic inflammation. Unlike standard CRP, which is sensitive enough only to detect acute infection or injury, hsCRP can detect the low-grade chronic inflammation that precedes and drives cardiovascular disease, metabolic dysfunction, and several cancers.

The JUPITER trial enrolled 17,802 adults with normal LDL (below 130 mg/dL) but elevated hsCRP. The trial found that statin therapy in this population reduced the rate of major cardiovascular events by 44 percent.^[4] That finding established that hsCRP adds independent predictive power beyond the standard lipid panel: you can have entirely normal cholesterol and still have a markedly elevated inflammatory cardiovascular risk that a standard panel will not catch. hsCRP is rarely included in routine annual blood work.

Five areas that actually need monitoring

The three examples above are not the only places where standard panels fall short. They illustrate a pattern that runs across the entire picture of metabolic and cardiovascular health: the markers that flag late are not the markers that predict early.

A longevity-oriented blood panel is organized differently from a standard clinical workup. Rather than testing for disease after symptoms suggest it, the goal is continuous monitoring of the underlying processes at a level of resolution that makes silent deterioration visible years before it becomes clinical.

The series that follows covers each of these five areas in detail: what to order, what the markers actually measure, what the lab considers normal and why that range can be misleading, and what optimal looks like for someone trying to stay healthy at 50 and at 70.

Metabolic health. Glucose regulation and insulin sensitivity. The area where dysfunction starts earliest, advances most silently, and does the most cumulative damage before standard markers flag anything. Fasting insulin, HOMA-IR, HbA1c, and the relationship between them.

Cardiovascular risk. Beyond cholesterol. ApoB, Lp(a), triglycerides, hsCRP, and homocysteine: the markers that predict arterial disease independently of LDL and that a standard lipid panel will miss entirely. The existing cholesterol article covers the mechanism; this series covers what to order and how to interpret it.

Hormonal balance. Thyroid, testosterone, DHEA-S, and IGF-1. Hormonal decline accelerates with age and has measurable effects on muscle mass, cognition, mood, and metabolic rate. These markers are rarely ordered in routine annual physicals, and the reference ranges for many of them are calibrated to populations whose average age and health status make “normal” a low bar.

Organ function. Liver enzymes, kidney markers, and a full blood count. These panels catch deterioration early, before symptoms appear and before damage becomes hard to reverse. ALT and GGT in particular are sensitive early indicators of metabolic liver stress that standard liver function panels can miss at normal sensitivity.

Nutritional status. Vitamin D, B12, ferritin, and the omega-3 index. Four markers where subclinical deficiency is common in developed-world populations, where the consequences are serious and long-term, and where standard annual blood work provides at best a partial picture. The longevity protocol article covers my personal supplementation; this article series covers why those markers matter and how to assess them.

---

The lab report you receive after a standard annual physical is not a report on your health. It is a report on whether you fall within a statistical band defined by a reference population of unclear composition. That is useful information. It is not enough information.

The articles that follow are a practical guide to what enough information looks like.

References

1. Sachdeva A, Cannon CP, Deedwania PC, et al. (2009). Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal, 157(1), 111–117. https://pubmed.ncbi.nlm.nih.gov/19101776/
2. Sniderman AD, Williams K, Contois JH, et al. (2011). A meta-analysis of low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337–345. https://pubmed.ncbi.nlm.nih.gov/21487090/
3. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412–419. https://pubmed.ncbi.nlm.nih.gov/3899825/
4. Ridker PM, Danielson E, Fonseca FAH, et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195–2207. https://www.nejm.org/doi/10.1056/NEJMoa0807646